    ----- Original Message -----

    From: Robert Meyers

    Sent: 06/20/2007 10:39 PM

    To: Lydia Wegman

    Subject: record

----- Forwarded by Robert Meyers/DC/USEPA/US on 06/20/2007 10:39 PM -----

Robert Meyers/DC/USEPA/US

06/20/2007 09:31 PM

To

"Farrell, Amy L."<EMAIL_ADDRESS> cc

<EMAIL_ADDRESS> Subject

Re: trying to call you

"Farrell, Amy L."<EMAIL_ADDRESS> 06/20/2007 09:22 PM

To

Robert Meyers/DC/USEPA/US@EPA

cc

Subject

Re: trying to call you

I am at OIRA. Susan is on phone now.

----- Original Message -----

From<EMAIL_ADDRESS><EMAIL_ADDRESS> To: Farrell, Amy L.

Sent: Wed Jun 20 21:20:37 2007

Subject: trying to call you


administered radioactivity. Feces accounted for 5.0-6.8% of the
administered radioactivity.  Within 24 hours, 89.0-91.7 % of the
administered radioactivity was excreted in the urine and 4.9-6.2% was
excreted in the feces.  Residual radioactivity in any given tissue at
168 hours post-dose was considerably less than 1% of the administered
dose.  Therefore, neither clothianidin nor its metabolites appeared to
exhibit potential for bioaccumulation. Excretory patterns did not
exhibit gender-related variability.

Both urinary and fecal metabolites were identified using TLC and
radioautography in conjunction with known standards and were quantified
by TLC/LSC .  The major metabolites in both urine and feces were the
parent compound (clothianidin) and TZNG
[N-(2-chlorothiazol-5-ylmethyl)-N-nitroguanidine] which resulted from
N-demethylation of clothianidin.  Extraction efficiencies were excellent
and most components in the urine and feces were adequately quantified
and characterized.  Based on the data from the oral administration of
[nitroimino-14C]-clothianidin the metabolism pathway proposed by the
investigators was supported.

870.7600	Dermal penetration - monkey	Dermal absorption as the sum of
urinary and fecal excretion and Cage/Pan/Chair Wash, Debris was 0.24 (+
0.11) as percent of dose. Adjustment of the direct absorption
determination was not necessary because recovery from the dermal dose
was >90%.

A value of 1% dermal absorption was considered appropriate for use in
risk assessment.  This estimation takes into account any variability
that would have likely occurred with testing several dose levels.

870.7800	Immunotoxicity – rat (adults)	Immunotoxicity NOAEL = 253
mg/kg/day (M/F)

Immunotoxicity LOAEL = not established

At the highest dose tested, 253 mg/kg/day, a decrease in body weights,
body weight gains, and food consumption was noted in adult males and
females.

Non-guideline	Special Study:

Neurotoxicity and pharmacology - mouse	NOAEL = 25 mg/kg/day (M/F)

ent signs of decreased spontaneous motor activity, tremors, and deep
respirations.

 TC \l1 " Appendix D:  Review of Human Research

	Page   PAGE  2  of   NUMPAGES  50